Geron Corporation (GERN): Price and Financial Metrics


Geron Corporation (GERN)

Today's Latest Price: $1.78 USD

0.01 (-0.56%)

Updated Dec 3 11:25am

Add GERN to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 389 in Biotech

See all "A" rated Strong Buy stocks

GERN Stock Summary

  • With a price/sales ratio of 1,485.95, Geron Corp has a higher such ratio than 99.48% of stocks in our set.
  • With a year-over-year growth in debt of 8,404.01%, Geron Corp's debt growth rate surpasses 99.49% of about US stocks.
  • As for revenue growth, note that GERN's revenue has grown -43.67% over the past 12 months; that beats the revenue growth of just 6.87% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Geron Corp, a group of peers worth examining would be SPCE, CBMG, ARNA, MRSN, and CRNX.
  • Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to www.geron.com.

GERN Stock Price Chart Interactive Chart >

Price chart for GERN

GERN Price/Volume Stats

Current price $1.78 52-week high $2.40
Prev. close $1.79 52-week low $0.75
Day low $1.78 Volume 549,491
Day high $1.82 Avg. volume 2,587,548
50-day MA $1.86 Dividend yield N/A
200-day MA $1.64 Market Cap 552.64M

Geron Corporation (GERN) Company Bio


Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.


GERN Latest News Stream


Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream


Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Geron Secures Loan Facility for Up to $75 Million

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 million with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank (SVB). The loan facility provides the Company with access to non-dilutive financial resources to support the imetelstat development program, as well as working capital and general corporate purposes. “This debt financing strengthens o

Business Wire | October 1, 2020

Geron (GERN) Presents At H.C. Wainwright 22nd Annual Global Investment Conference

The following slide deck was published by Geron Corporation in conjunction with this event....

SA Transcripts on Seeking Alpha | September 15, 2020

Geron to Present at the H.C. Wainwright Global Investment Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, to be hosted in a virtual format, on Monday, September 14, 2020 at 2:30 p.m. ET. A live audio webcast of the presentation will be available on Geron’s website, www.geron.com/investors/events. If you

Business Wire | September 9, 2020

Geron Corporation Reports Second Quarter 2020 Financial Results and Current Events

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, 2020. The Company will host a conference call today at 4:30 p.m. ET to discuss second quarter financial results and current events. “In the second quarter, we achieved a number of key milestones that have changed the trajectory of the Company,” said John A. Scarlett, M.D., Chairman and Chief Executive Offi

Business Wire | August 6, 2020

Geron to Announce Second Quarter Financial Results on August 6, 2020

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August 6, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. A live, listen-only webcast will be available on the Company’s website at www.ge

Business Wire | July 30, 2020

Read More 'GERN' Stories Here

GERN Price Returns

1-mo -0.56%
3-mo -2.73%
6-mo 15.58%
1-year 19.46%
3-year -5.82%
5-year -64.82%
YTD 30.88%
2019 36.00%
2018 -44.44%
2017 -13.04%
2016 -57.23%
2015 48.92%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6988 seconds.